On Tuesday, Poseida Therapeutics Inc (NASDAQ: PSTX) opened higher 0.11% from the last session, before settling in for the closing price of $9.48. Price fluctuations for PSTX have ranged from $1.87 to $9.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 53.46%. Company’s average yearly earnings per share was noted 48.40% at the time writing. With a float of $67.38 million, this company’s outstanding shares have now reached $97.41 million.
The extent of productivity of a business whose workforce counts for 330 workers is very important to gauge. In terms of profitability, gross margin is 95.42%, operating margin of -41.43%, and the pretax margin is -40.25%.
Poseida Therapeutics Inc (PSTX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Poseida Therapeutics Inc is 30.86%, while institutional ownership is 55.76%. The most recent insider transaction that took place on Dec 10 ’24, was worth 283,866. In this transaction Executive Chairman of this company sold 30,000 shares at a rate of $9.46, taking the stock ownership to the 651,291 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Executive Chairman sold 30,000 for $9.27, making the entire transaction worth $278,100. This insider now owns 651,291 shares in total.
Poseida Therapeutics Inc (PSTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 48.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.70% during the next five years compared to -12.83% drop over the previous five years of trading.
Poseida Therapeutics Inc (NASDAQ: PSTX) Trading Performance Indicators
Check out the current performance indicators for Poseida Therapeutics Inc (PSTX). In the past quarter, the stock posted a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.68 in one year’s time.
Technical Analysis of Poseida Therapeutics Inc (PSTX)
The latest stats from [Poseida Therapeutics Inc, PSTX] show that its last 5-days average volume of 1.07 million was superior to 0.74 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 51.52%. Additionally, its Average True Range was 0.24.
During the past 100 days, Poseida Therapeutics Inc’s (PSTX) raw stochastic average was set at 98.76%, which indicates a significant increase from 64.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 7.02% in the past 14 days, which was lower than the 199.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.40, while its 200-day Moving Average is $3.53. Now, the first resistance to watch is $9.51. This is followed by the second major resistance level at $9.53. The third major resistance level sits at $9.56. If the price goes on to break the first support level at $9.46, it is likely to go to the next support level at $9.43. The third support level lies at $9.41 if the price breaches the second support level.
Poseida Therapeutics Inc (NASDAQ: PSTX) Key Stats
There are currently 97,774K shares outstanding in the company with a market cap of 924.94 million. Presently, the company’s annual sales total 64,700 K according to its annual income of -123,430 K. Last quarter, the company’s sales amounted to 71,750 K and its income totaled 20,240 K.
